Page last updated: 2024-11-06

methylprednisolone aceponate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methylprednisolone aceponate is a synthetic corticosteroid medication that is used to treat a variety of inflammatory conditions. It is a prodrug, meaning that it is inactive when administered but is converted to the active drug methylprednisolone in the body. Methylprednisolone aceponate is typically administered topically, either as a cream or ointment, to treat skin conditions such as eczema, psoriasis, and dermatitis. It is also sometimes used to treat inflammatory conditions in the eyes and ears. The synthesis of methylprednisolone aceponate involves the chemical modification of the steroid molecule to make it more potent and longer-acting. The drug is designed to have a high affinity for the glucocorticoid receptor, which is a protein that is involved in the regulation of inflammation. When methylprednisolone aceponate binds to the glucocorticoid receptor, it triggers a cascade of events that lead to the suppression of inflammation. Methylprednisolone aceponate is an important drug because it can effectively treat a wide range of inflammatory conditions. It is relatively safe when used topically, although it can have side effects such as skin thinning, acne, and stretch marks. The drug is studied extensively in order to understand its mechanism of action, to identify new uses for the drug, and to develop safer and more effective alternatives. Methylprednisolone aceponate is a valuable tool for the treatment of inflammatory conditions, and its continued study is likely to lead to new and improved therapies.'

methylprednisolone aceponate: RN given for (6alpha,11beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63019
CHEMBL ID1697782
CHEBI ID135762
SCHEMBL ID3466
MeSH IDM0209242

Synonyms (51)

Synonym
AC-6842
sh-440
advantan
methylprednisolone aceponate
zk-91588
86401-95-8
(6alpha,11beta)-21-(acetyloxy)-11-hydroxy-6-methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate
advantan (tn)
methylprednisolone aceponate (inn)
D07203
zk91588
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6-alpha,11-beta)-
methylprednisolone aceponate [inn]
11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, 21-acetate 17-propionate
c27h36o7
methylprednisoloni aceponas [latin]
aceponate de methylprednisolone [french]
aceponato de metilprednisolona [spanish]
brn 5663614
CHEBI:135762
[(6s,8s,9s,10r,11s,13s,14s,17r)-17-(2-acetyloxyacetyl)-11-hydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl] propanoate
A841638
(6s,8s,9r,11s,13s,14s,17r)-17-(2-acetoxyacetyl)-11-hydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl propionate
CHEMBL1697782
AKOS016003120
methylprednisoloni aceponas
unii-et54w9j4u2
aceponato de metilprednisolona
aceponate de methylprednisolone
et54w9j4u2 ,
11.beta.,17,21-trihydroxy-6.alpha.-methylpregna-1,4-diene-3,20-dione, 21-acetate 17-propionate
6.alpha.-methylprednisolone aceponate
methylprednisolone aceponate [who-dd]
methylprednisolone aceponate [jan]
methylprednisolone aceponate [mi]
6-.alpha.-methylprednisolone aceponate
SCHEMBL3466
21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione
DALKLAYLIPSCQL-YPYQNWSCSA-N
DTXSID2023301
DB14643
DS-18010
Q6824052
pregna-1,4-diene-3,20-dione,21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6a,11b)-
methylprednisolone-aceponate
NCGC00510142-01
6?-methyl prednisolone aceponate
CS-0023308
(1r,3as,3bs,5s,9ar,9bs,10s,11as)-1-[2-(acetyloxy)acetyl]-10-hydroxy-5,9a,11a-trimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl propanoate
EN300-7414988
HY-103025

Research Excerpts

Overview

Methylprednisolone aceponate (MPA) is a non-halogenated corticosteroid with a methyl group at C6, which confers higher intrinsic activity. MPA has demonstrated efficacy and safety in acute and maintenance programmes in infants and children.

ExcerptReferenceRelevance
"Methylprednisolone aceponate (MPA) is a non-halogenated corticosteroid with a methyl group at C6, which confers higher intrinsic activity."( Methylprednisolone aceponate for atopic dermatitis.
Torrelo, A, 2017
)
2.62
"Methylprednisolone aceponate is a potent fourth generation corticosteroid which has demonstrated efficacy and safety in acute and maintenance programmes in infants and children."( Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.
Blume-Peytavi, U; Wahn, U, 2011
)
1.31

Effects

Methylprednisolone aceponate (MPA) has been shown to provide rapid, reliable and highly effective treatment of eczematous disorders. The efficacy is comparable to that of most reference topical corticosteroids.

ExcerptReferenceRelevance
"Methylprednisolone aceponate (MPA) has been shown to provide rapid, reliable and highly effective treatment of eczematous disorders, with an efficacy comparable to that of most reference topical corticosteroids. "( Methylprednisolone aceponate in eczema and other inflammatory skin disorders -- a clinical update.
Ruzicka, T, 2006
)
3.22
"Methylprednisolone aceponate (MPA) has recently been synthesized."( Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers.
Jahn, P; Kecskés, A; Kuhlmann, RK; Lange, L; Wendt, H, 1992
)
1.26

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Drug-related adverse events were only observed in the tacrolimus group."( Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis.
Arcangeli, F; Belloni-Fortina, A; Bieber, T; Fölster-Holst, R; Städtler, G; Vick, K; Worm, M, 2007
)
0.65
" MPA has an optimized efficacy/safety profile with minimal local or systemic adverse effects."( Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate.
Luger, TA, 2011
)
0.59

Dosage Studied

ExcerptRelevanceReference
" This review examines the role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management, with reference to the chemical structure, pharmacokinetics, efficacy in AD, safety assessed in preclinical and clinical trials and dosing considerations."( Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate.
Luger, TA, 2011
)
0.81
" Naringenin, naringenin chalcone, and quercetin all showed strong antiallergic activity after intravenous dosing (0."( In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
Boix Montañés, A; Escribano-Ferrer, E; Garcia-Sala, X; Lamuela-Raventos, RM; Queralt Regué, J, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1537242Antiallergic activity in CD-1 mouse model of IgE/DNP-BSA-stimulated passive cutaneous anaphylaxis assessed as inhibition of vascular permeability at 0.1% administered topically immediately after sensitization by Evans blue extravasation assay2019Journal of natural products, 02-22, Volume: 82, Issue:2
In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (18.75)18.2507
2000's14 (21.88)29.6817
2010's35 (54.69)24.3611
2020's3 (4.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.30 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index96.49 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (56.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (25.35%)5.53%
Reviews9 (12.68%)6.00%
Case Studies21 (29.58%)4.05%
Observational0 (0.00%)0.25%
Other23 (32.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life: an Observational Study [NCT04900948]Phase 4108 participants (Actual)Interventional2017-12-10Completed
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis Wi [NCT00185510]Phase 4250 participants (Actual)Interventional2005-03-31Completed
Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). [NCT01529320]Phase 118 participants (Actual)Interventional2012-02-29Completed
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test [NCT00236171]14 participants (Actual)Interventional2004-09-30Completed
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids [NCT02798523]Phase 133 participants (Actual)Interventional2017-01-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02798523 (1) [back to overview]Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)

Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)

Number of participants (biological replicates) that were successfully sampled for RNA-seq differential gene expression analysis in glucocorticoid-treated immune cells. The analysis employed a cutoff value of < 5% false-discovery rate (FDR) to select the transcripts that were considered differentially expressed at each time point. The resulting gene lists were contrasted to determine which genes were uniquely differentially expressed in different cell types. (NCT02798523)
Timeframe: Up to 2 or 4 hours post infusion depending on group

InterventionParticipants (Count of Participants)
Up to 2 Hours Post Infusion5
Up to 4 Hours Post Infusion20

[back to top]